Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts [1]

Leukemia

Volumn 18, Issue 9, 2004, Pages 1539-1540

  Lee, J J ^a,b   Kim, H J ^a,b   Kim, Y J ^c   Lee, S ^c   Hwang, J Y ^c   Kim, Y L ^c   Kim, D W ^c  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; INTERFERON; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; BLAST CELL CRISIS; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; CYTOPENIA; DRUG RESPONSE; DRUG WITHDRAWAL; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; LETTER; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; CHROMOSOME ANALYSIS; GENETICS; MIDDLE AGED; MYELOID LEUKEMIA;

ADULT; ANTINEOPLASTIC AGENTS; BLAST CRISIS; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERONS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT FAILURE;

EID: 4444334312     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403454     Document Type: Letter

References (8)

1. Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990; 76: 1819-1824.
2. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88: 2410-2414.
3. Briz M, Vilches C, Cabrera R, Fores R, Fernandez MN. Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript. Blood 1997; 90: 5024-5025.
4. How GF, Tan LT, Lim LC. Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction - is it truly a benign disease? Leukemia 1998; 12: 1166-1167.
5. Polak J, Koza V, Cetkovsky P, Haskovec C. An accelerated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr. Bone Marrow Transplant 2000; 25: 1109-1110.
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
7. Kim YJ, Kim DW, Lee S, Kim HJ, Kim YL, Hwang JY et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the bcr-abl gene after hematopoietic stem cell transplantation in CML. Eur J Haematol 2002; 68: 272-280.
8. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.